Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
- 12 August 2008
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 14 (2), 180-192
- https://doi.org/10.1016/j.ccr.2008.06.014
Abstract
No abstract availableThis publication has 62 references indexed in Scilit:
- A membrane capture assay for lipid kinase activityNature Protocols, 2007
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJCI Insight, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenanceCancer Cell, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001